Wuhan Changlian Laifu Pharmaceutical Co., Ltd.

To evaluate the relative bioavailability and bioequivalence of the test and reference preparations of lamivudine tablets after single-dose (24 subjects) and post-meal (24 subjects) oral administration in 48 healthy subjects, and to observe the tolerability and safety of lamivudine tablets in healthy subjects, so as to provide a reference for the application and clinical design of the drug.

Pharmacokinetic parameters were used as the primary endpoint evaluation indicators to compare the pharmacokinetic behaviors of the test preparation, ramelteon tablets provided by Wuhan Changlian Laifu Pharmaceutical Co., Ltd., and the reference preparation, ramelteon tablets (manufacturer: Takeda Pharmaceutical Company Limited, Japan, trade name: Rozerem®), in healthy subjects after oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations.

Pharmacokinetic parameters were used as the primary endpoint evaluation indicators to compare the pharmacokinetic behaviors of the test preparation, montelukast sodium chewable tablets provided by Wuhan Changlian Laifu Pharmaceutical Co., Ltd., and the reference preparation, montelukast sodium chewable tablets (manufacturer: Merck Sharp & Dohme Ltd., trade name: Singulair®) in healthy subjects after oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations.